Abstract
Objective
The present study was designed to evaluate the effects of adjuvant chemotherapy (CT) vs. radiotherapy (RT, alone or combined with CT) on the prognosis of patients with high-risk, early-stage (stage I and stage II) endometrioid endometrial carcinoma.
Methods
This single-center retrospective clinical study was conducted in Union Hospital, Tongji Medical College, Huazhong University of Science and Technology between 2010 and 2019. In the present study, endometrioid endometrial carcinoma patients, who underwent total hysterectomy and bilateral salpingo-oophorectomy followed by postoperative adjuvant CT or RT (alone or combined with CT), and were diagnosed with stage IA grade 2/3 with lymph-vascular space invasion (LVSI), and stage IB with two or more uterine risks, including old age, histological grade 2 or 3, LVSI and stage II, were included. According to the postoperative adjuvant therapy, all eligible patients were divided into two groups: CT group and RT (RT±CT) group. The primary objective was to investigate overall survival (OS) and disease-free survival (DFS) between the CT and RT groups. Grade 3 or worse adverse events were also presented in the present study.
Results
A total of 145 eligible patients were included. Among these patients, 97 patients underwent adjuvant CT and 48 patients underwent adjuvant RT (RT±CT). The median follow-up was 47.2 months, and the five-year OS rate was 92.7% in the CT group and 88.6 % in the RT group [hazard ratio (HR): 0.81, 95% confidence interval (CI): 0.22–2.99). The 5-year DFS rate for the two groups was 85.7% and 80.2%, respectively (HR: 0.82, 95% CI: 0.33–2.05). The cumulative incidence of local-regional disease recurrence at 60 months of follow-up was 6.2% in the CT group and 6.3% in the RT group (HR=1.11; 95%CI: 0.28–4.35). The cumulative incidence of distant recurrence at 60 months of follow-up was 5.2% in the CT group and 10.4% in the RT group (HR=0.65; 95%CI: 0.19–2.24). Both groups of patients were well-tolerant, and the only grade 3 or worse adverse events were neutropenia and thrombocytopenia.
Conclusion
There was no difference in efficacy for adjuvant CT or adjuvant RT (RT±CT) in high-risk, early-stage endometrioid endometrial carcinoma. CT exhibited a trend of reducing the distant relapse, although there was no significant difference, when compared with adjuvant RT (RT±CT).
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Wang Y, Yang JX. Fertility-preserving treatment in women with early endometrial cancer: the Chinese experience. Cancer Manag Res, 2018,10:6803–6813
Amant F, Mirza MR, Koskas M, et al. Cancer of the corpus uteri. Int J Gynaecol Obstet, 2018,143(Suppl 2):37–50
Siegel RL, Miller KD, Jemal A. Cancer statistics. 2020. CA Cancer J Clin, 2020,70(1):7–30
Hyun JP, Eun JN, Sunghoon K, et al. The benefit of adjuvant chemotherapy combined with postoperative radiotherapy for endometrial cancer: a meta-analysis. Eur J Obstet Gynecol Reprod Biol, 2013,170(1):39–44
Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the results of treatment in gynecological cancer. Int J Gynecol Obstet, 2006,95:S105–S143
Morrow P, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol, 1991,40:55–65
Jutzi L, Hoskins P, Lim P, et al. The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma. Gynecol Oncol, 2013,131(3):581–585
Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet, 2000,355:1404–1415
Keys HM, Roberts JA, Brunetto VL, et al. Gynecologic Oncology Group (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol, 2004,92:744–751
Creutzberg CL, Nout RA, Lybeert ML, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-I trial for endometrial carcinoma. Radiat Oncol Biol Phys, 2011,81(4):631–639
Blake P, Swart AM, Orton J, et al. ASTEC/EN.5 Study Group. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCICCTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet, 2009,373:137–146
Susumu N, Sagae S, Udagawa Y, et al. Japanese Gynecologic Oncology Group. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol, 2008,108(1):226–259
Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet, 2010,375:816–839
Song J, Le T, Hopkins L, et al. Treatment of early stage high-risk endometrioid-type endometrial cancer and patterns of disease relapse: a retrospective analysis. Adv Radiat Oncol, 2020,5(5):910–919
Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol, 2006,24:36–44
Matei D, Filiaci V, Randall ME, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med, 2019,380(24):2317–2326
Gómez-Raposo C, Merino Salvador M, Aguayo Zamora C, et al. Adjuvant chemotherapy in endometrial cancer. Cancer Chemother Pharmacol, 2020,85(3):477–486
Kodama J, Seki N, Ojima Y, et al. Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus. Eur J Obstet Gynecol Reprod Biol, 2017,131(1):76–80
Aoki Y, Watanabe M, Amikura T, et al. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer. Gynecologic Oncology, 2004,94: 333–339
NCCN The NCCN Uterine Neoplasms clinical practice guidelines in oncology (version 2.2021)(2021-05-07) Guidelines Detail (nccn.org)
Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. National Cancer Institute. November 27, 2017. Common Terminology Criteria for Adverse Events (CTCAE) (cancer.gov)
Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer, 2006,95:266–271
Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol, 2006,24(1):36–44
Susumu N, Sagae S, Udagawa Y, et al. Japanese Gynecologic Oncology Group. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study. Gynecol Oncol, 2008,108:226–233
Kandoth NC, Schultz N, Cherniack AD, et al. Cancer genome atlas research, integrated genomic characterization of endometrial carcinoma. Nature, 2013,497:67–73
Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and Paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol, 2020,38(33):3841–3850
Frimer M, Miller EM, Shankar V, et al. Adjuvant pelvic radiation “sandwiched” between paclitaxel/Carboplatin chemotherapy in women with completely resected uterine serous carcinoma: long-term follow-up of a prospective phase 2 trial. Int J Gynecol Cancer, 2018,28(9):1781–1788
Secord AA, Havrilesky LJ, O’Malley DM, et al. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecol Oncol, 2009, 114:442–447
de Boer SM, Powell ME, Mileshkin L, et al. PORTEC study group. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): Final results of an international, open-label, multicenter, randomised, phase 3 trial. Lancet Oncol, 2018,19:295–309
de Boer SM, Powell ME, Mileshkin L, et al. PORTEC study group. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): An open label, multicenter, randomised, phase 3 trial. Lancet Oncol, 2016,17:1114–1126
Greven K, Winter K, Underhill K, et al. Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol, 2006,103:155–159
Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer—results from two randomised studies. Eur J Cancer, 2010,46:2422–2431
McMeekin DS, Filiaci VL, Thigpen JT, et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a gynecologic oncology group study. Gynecol Oncol, 2007,106:16–22
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
The authors have no conflict of interests to declare.
Author Ze-hua WANG is a member of the Editorial Board for Current Medical Science. The paper was handled by the other editor and has undergone rigorous peer review process. Author Ze-hua WANG was not involved in the journal’s review of, or decision related to, this manuscript.
Rights and permissions
About this article
Cite this article
Wu, M., Yang, Yn., Huang, Yh. et al. Adjuvant Chemotherapy versus Radiotherapy in High-risk, Early-stage Endometrioid Endometrial Carcinoma. CURR MED SCI 42, 185–191 (2022). https://doi.org/10.1007/s11596-021-2437-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11596-021-2437-8